GSK Perspective on Universal Vaccination Against Influenza

1
GSK Perspective on Universal Vaccination Against
Influenza

• Varsha K. Jain, MD
• Director, Clinical RD and Medical Affairs,
• Vaccine for Virus Diseases, North America
• GlaxoSmithKline

2
GSKs Commitment to Influenza Vaccines

• Committed to be part of the long term solution of
  the countrys influenza public health concern
• Responded to 2004/5 Influenza vaccine shortage,
  worked with FDA and CDC
• Pursued FLUARIX licensure for adults in time for
  the 2005/6 season.

3
GSKs Commitment to Influenza Vaccines (Cont)

• GSK is an advocate of childhood vaccination
• GSK recognizes universal recommendations are the
  most successful national vaccination policies
• Especially for children
• GSK is pursuing pediatric indication for FLUARIX

4
GSKs Commitment for Influenza Prevention

• Expanded manufacturing in Dresden, Germany
• double influenza vaccine production capacity by
  2008
• Acquired manufacturing facility in US (Marietta,
  PA)
• cell culture based inter-pandemic and pandemic
  vaccines
• Proposal to acquire ID Biomedical
• manufacturing facilities in Canada and US
• Developing improved influenza vaccines
• using novel adjuvant

5
Supply/Demand and Infrastructure

• Supply should meet the demand
• Demand will increase if influenza vaccination is
  universally recommended
• Partnership to avoid over/under supply
• Build infrastructure for yearly influenza
  vaccination to children and adults
• same infrastructure can help pandemic
  preparation

6
Conclusion

• GSK supports universal vaccination against
  Influenza
• GSK is taking steps to expand and diversify
  influenza vaccine supply
• Essential to see a multiyear plan for universal
  vaccination
• GSK will respond to that plan by further building
  its capacity to supply